These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38452616)

  • 81. Evaluation of Function and Features of Human Induced Pluripotent Stem Cell-Derived Small Intestinal Epithelial Cells for Analyzing Peptide Drug Intestinal Absorption Profiles.
    Itagaki M; Kamei N; Takeda-Morishita M
    J Pharm Sci; 2023 Sep; 112(9):2591-2595. PubMed ID: 37230251
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.
    Lu S; Nand RA; Yang JS; Chen G; Gross AS
    Eur J Clin Pharmacol; 2018 Mar; 74(3):285-296. PubMed ID: 29181698
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Spectroscopic observations of β-eudesmol binding to human cytochrome P450 isoforms 3A4 and 1A2, but not to isoforms 2C9, 2C19, and 2D6.
    Krenc D; Na-Bangchang K
    Xenobiotica; 2022 Feb; 52(2):199-208. PubMed ID: 35139770
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population.
    Tang SW; Lv XZ; Chen R; Wu SS; Yang ZR; Chen DF; Zhan SY
    Clin Exp Pharmacol Physiol; 2013 May; 40(5):326-32. PubMed ID: 23469989
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Interaction of silymarin components and their sulfate metabolites with human serum albumin and cytochrome P450 (2C9, 2C19, 2D6, and 3A4) enzymes.
    Faisal Z; Mohos V; Fliszár-Nyúl E; Valentová K; Káňová K; Lemli B; Kunsági-Máté S; Poór M
    Biomed Pharmacother; 2021 Jun; 138():111459. PubMed ID: 33706132
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels.
    Treijtel N; Collins C; van Bruijnsvoort M; Fuhr R; Ernault E; Gangaram-Panday S; Passier P
    Clin Pharmacol Drug Dev; 2019 May; 8(4):529-540. PubMed ID: 30730615
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
    Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
    Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The effect of polymorphic metabolism enzymes on serum phenytoin level.
    Ozkaynakci A; Gulcebi MI; Ergeç D; Ulucan K; Uzan M; Ozkara C; Guney I; Onat FY
    Neurol Sci; 2015 Mar; 36(3):397-401. PubMed ID: 25311916
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Quantitative Atlas of Cytochrome P450, UDP-Glucuronosyltransferase, and Transporter Proteins in Jejunum of Morbidly Obese Subjects.
    Miyauchi E; Tachikawa M; Declèves X; Uchida Y; Bouillot JL; Poitou C; Oppert JM; Mouly S; Bergmann JF; Terasaki T; Scherrmann JM; Lloret-Linares C
    Mol Pharm; 2016 Aug; 13(8):2631-40. PubMed ID: 27347605
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Generation of enterocyte-like cells from human induced pluripotent stem cells for drug absorption and metabolism studies in human small intestine.
    Ozawa T; Takayama K; Okamoto R; Negoro R; Sakurai F; Tachibana M; Kawabata K; Mizuguchi H
    Sci Rep; 2015 Nov; 5():16479. PubMed ID: 26559489
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Cytochrome P450 1A1, 2C9, 2C19, and 3A4 Polymorphisms Account for Interindividual Variability of Toxicological Drug Metabolism in Cynomolgus Macaques.
    Uno Y; Uehara S; Murayama N; Yamazaki H
    Chem Res Toxicol; 2018 Dec; 31(12):1373-1381. PubMed ID: 30412386
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
    Gentile DM; Verhoeven CH; Shimada T; Back DJ
    J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.
    Bahar MA; Setiawan D; Hak E; Wilffert B
    Pharmacogenomics; 2017 May; 18(7):701-739. PubMed ID: 28480783
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity.
    Kvitne KE; Åsberg A; Johnson LK; Wegler C; Hertel JK; Artursson P; Karlsson C; Andersson S; Sandbu R; Skovlund E; Christensen H; Jansson-Löfmark R; Hjelmesaeth J; Robertsen I
    Clin Transl Sci; 2022 Nov; 15(11):2685-2696. PubMed ID: 36037309
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells.
    Prueksaritanont T; Gorham LM; Hochman JH; Tran LO; Vyas KP
    Drug Metab Dispos; 1996 Jun; 24(6):634-42. PubMed ID: 8781778
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Individual metabolic capacity evaluation of cytochrome P450 2C19 by protein and activity in the small intestinal mucosa of Japanese pancreatoduodenectomy patients.
    Hayashi M; Matsumoto N; Takenoshita-Nakaya S; Takeba Y; Watanabe M; Kumai T; Takagi M; Tanaka M; Otsubo T; Kobayashi S
    Biol Pharm Bull; 2011; 34(1):71-6. PubMed ID: 21212520
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs.
    Hirota T; Eguchi S; Ieiri I
    Drug Metab Pharmacokinet; 2013; 28(1):28-37. PubMed ID: 23165865
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Differing Membrane Interactions of Two Highly Similar Drug-Metabolizing Cytochrome P450 Isoforms: CYP 2C9 and CYP 2C19.
    Mustafa G; Nandekar PP; Bruce NJ; Wade RC
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31487853
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Evaluation of Barrier Functions in Human iPSC-Derived Intestinal Epithelium.
    Yamada S; Kanda Y
    Methods Mol Biol; 2021; 2367():27-35. PubMed ID: 33661485
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
    De Zwart L; Snoeys J; Jacobs F; Li LY; Poggesi I; Verboven P; Goris I; Scheers E; Wynant I; Monshouwer M; Mamidi RNVS
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1107-1118. PubMed ID: 34273250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.